Eliem Therapeutics, Inc. (ELYM)
Largest Insider Buys in Sector
ELYM Stock Price History Chart
ELYM Stock Performance
About Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
Insider Activity of Eliem Therapeutics, Inc.
Over the last 12 months, insiders at Eliem Therapeutics, Inc. have bought $0 and sold $8,982 worth of Eliem Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Eliem Therapeutics, Inc. have bought $50M and sold $8,982 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,200,000 shares for transaction amount of $40M was made by RA CAPITAL MANAGEMENT, L.P. () on 2021‑08‑12.
List of Insider Buy and Sell Transactions, Eliem Therapeutics, Inc.
| 2024-06-20 | Sale | Pimblett Emily | CHIEF ACCOUNTING OFFICER | 1,245 0.0036% | $7.21 | $8,982 | -2.32% | |
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. | 3.2M 14.8009% | $12.50 | $40M | -46.89% | |||
| 2021-08-12 | AI ETI LLC | 10 percent owner | 800,000 3.7002% | $12.50 | $10M | -46.89% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $36.03M | 45.21 | 13.15M | 0% | +$0 | 0.04 | |
| Bml Capital Management Llc | $6.01M | 7.54 | 2.19M | +0.63% | +$37,653.08 | 4.58 | |
| Driehaus Capital Management LLC | $2.22M | 2.79 | 811,680 | 0% | +$0 | 0.02 | |
| The Vanguard Group | $850,732.00 | 1.07 | 310,486 | 0% | +$0 | <0.0001 | |
| Atom Investors Lp | $214,476.00 | 0.27 | 78,276 | 0% | +$0 | 0.03 | |
| Geode Capital Management | $182,616.00 | 0.23 | 66,626 | 0% | +$0 | <0.0001 | |
| Bridgeway Capital Management | $151,311.00 | 0.19 | 55,223 | 0% | +$0 | <0.01 | |
| Northern Trust | $119,103.00 | 0.15 | 43,468 | -10.77% | -$14,368.64 | <0.0001 | |
| BlackRock | $83,405.00 | 0.11 | 30,440 | -2.26% | -$1,931.69 | <0.0001 | |
| Tudor Investment Corp Et Al | $80,737.00 | 0.1 | 29,466 | -0.08% | -$65.76 | <0.01 | |
| State Street | $59,458.00 | 0.08 | 21,700 | 0% | +$0 | <0.0001 | |
| Millennium Management LLC | $55,090.00 | 0.07 | 20,106 | +9.13% | +$4,611.38 | <0.0001 | |
| Chicago Partners Wealth Advisors | $45,390.00 | 0.04 | 12,104 | -0.46% | -$210.00 | <0.01 | |
| Renaissance Technologies | $29,000.00 | 0.04 | 10,617 | +0.13% | +$38.24 | <0.0001 | |
| Advisor Group Holdings Inc | $21,665.00 | 0.03 | 8,333 | 0% | +$0 | <0.0001 | |
| UBS | $16,235.00 | 0.02 | 5,925 | New | +$16,235.00 | <0.0001 | |
| Tower Research Capital | $9,880.00 | 0.01 | 3,606 | +4.37% | +$413.72 | <0.0001 | |
| Morgan Stanley | $4,683.00 | 0.01 | 1,709 | 0% | +$0 | <0.0001 | |
| Qube Research & Technologies | $2,688.00 | <0.01 | 981 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $137.00 | <0.01 | 50 | +4.17% | +$5.48 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 63 | +75% | +$0 | <0.0001 |